SCHEMBL235829

SCHEMBL235829

O=C(O)c1cc(Cl)c2c(c1Cl)C1(OC2=O)c2cc(Cl)c(O)cc2Oc2cc(O)c(Cl)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMAD3 P84022 2/20 0.40
HPGD P15428 5/20 0.40
ALDH1A1 P00352 4/20 0.40
HSD17B10 Q99714 4/20 0.40
BRCA1 P38398 2/20 0.40
ALOX15 P16050 2/20 0.40
ALOX12 P18054 2/20 0.40
CYP2C9 P11712 1/20 0.40
RECQL P46063 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
THRB P10828 2/20 0.38
BLM P54132 2/20 0.38
TSHR P16473 2/20 0.38
CASP1 P29466 2/20 0.38
CYP3A4 P08684 1/20 0.38
MAPK1 P28482 1/20 0.38
HIF1A Q16665 1/20 0.38
GLB1 P16278 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29461682 1.00 SMAD3 (0.40) SMAD3HPGDALDH1A1HSD17B10BRCA1
Cyanide SCHEMBL6533545 0.97 SMAD3 (0.38) SMAD3HPGDALDH1A1HSD17B10BRCA1
SCHEMBL6045753 0.92 ALDH1A1 (0.47) SMAD3HPGDALDH1A1HSD17B10BRCA1
SCHEMBL1022908 0.91 SMAD3 (0.40) SMAD3HPGDALDH1A1HSD17B10BRCA1
SCHEMBL6816059 0.87 SMAD3 (0.36) SMAD3HPGDALDH1A1HSD17B10BRCA1
SCHEMBL231207 0.85 ALDH1A1 (0.58) SMAD3HPGDALDH1A1HSD17B10BRCA1
SCHEMBL5489541 0.83 SMAD3 (0.35) SMAD3HPGDALDH1A1HSD17B10BRCA1
SCHEMBL29838734 0.83 SMAD3 (0.35) SMAD3HPGDALDH1A1HSD17B10BRCA1
SCHEMBL29838717 0.83 SMAD3 (0.35) SMAD3HPGDALDH1A1HSD17B10BRCA1
SCHEMBL1444923 0.83 SMAD3 (0.57) SMAD3HPGDALDH1A1HSD17B10BRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024143925-A1 ANTIBODY OR PEPTIDE BINDING SPECIFICALLY TO RNASE A, IMMUNOASSAY DEVICE AND METHOD FOR DETECTING RNASE A, AND METHOD FOR COLLECTING RNASE A 연세대학교 산학협력단 2024-07-04 WO claimed
US-11906523-B2 Signaling conjugates and methods of use VENTANA MEDICAL SYSTEMS, INC. (US) 2024-02-20 US claimed
EP-4279498-A1 SWITCHING PEPTIDE, IMMUNOASSAY DEVICE COMPRISING SAME, AND IMMUNOASSAY METHOD USING SAME Optolane Technologies Inc. (KR) 2023-11-22 EP claimed
US-11248260-B2 Quantitative amplification normalization with quenchers BIO-RAD LABORATORIES, INC. (US) 2022-02-15 US claimed
EP-3875599-A1 METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS Astellas Institute for Regenerative Medicine (US) 2021-09-08 EP claimed
EP-2596119-B1 METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS ASTELLAS INST FOR REGENERATIVE MEDICINE (US) 2021-04-28 EP claimed
US-10961342-B2 Resin formulation and uses thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-03-30 US claimed
US-10809196-B2 Quencher containing water soluble polymer-conjugated nanomaterial and use thereof LEMONEX INC. (KR) 2020-10-20 US claimed
US-20200087443-A1 A Resin Formulation and Uses Thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-03-19 US claimed
US-20180306718-A1 QUENCHER CONTAINING WATER SOLUBLE POLYMER-CONJUGATED NANOMATERIAL AND USE THEREOF LEMONEX INC. (KR) 2018-10-25 US claimed
EP-0777749-B1 COUPLED AMPLIFICATION AND LIGATION METHOD PE CORP NY (US) 2002-10-30 EP claimed
US-20020115067-A1 Asymmetric benzoxanthene dye labelling reagents THE PERKIN-ELMER CORPORATION 2002-08-22 US claimed
JP-3102800-B2 2000-10-23 JP claimed
US-6130073-A DETECTING A TARGET NUCLEOTIDE SEQUENCES IN A SAMPLE; AMPLIFYING TARGET NUCLEOTIDE SEQUENCES BY PRIMER EXTENSION, LIGATING OLIGONUCLEOTIDE PROBES AND DETECTING LIGATION PRODUCTS PERKIN-ELMER CORP., APPLIED BIOSYSTEMS DIVISION (US) 2000-10-10 US claimed
US-6020481-A FLUORESCENT LABELING REAGENTS; DIDEOXY POLYNUCLEOTIDE SEQUENCING AND FRAGMENT ANALYSIS METHODS. THE PERKIN-ELMER CORPORATION (US) 2000-02-01 US claimed
EP-0891393-B1 ASYMMETRIC BENZOXANTHENE DYES PERKIN ELMER CORP (US) 1999-06-30 EP claimed
US-5912148-A DETECTION OF POLYNUCLEOTIDE IN SAMPLE BY POLYMERASE CHAIN REACTION AND LIGATION OF OLIGONUCLEOTIDE PROBES WHICH HYBRIDIZE TO AMPLIFICATION PRODUCT, DETECTION OF LIGATION PRODUCT IN ONE REACTION VESSEL PERKIN-ELMER CORPORATION APPLIED BIOSYSTEMS (US) 1999-06-15 US claimed
WO-1999009212-A1 TELOMERASE ASSAY QUEEN MARY & WESTFIELD COLLEGE (GB) 1999-02-25 WO claimed
EP-0777749-A2 COUPLED AMPLIFICATION AND LIGATION METHOD PERKIN-ELMER CORPORATION (US) 1997-06-11 EP claimed
WO-1996006190-A2 COUPLED AMPLIFICATION AND LIGATION METHOD PERKIN-ELMER CORPORATION (US) 1996-02-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11906523-B2 Signaling conjugates and methods of use CABLES1, ILK, BCR SMAD3 1210/4885HPGD 3734/4885ALDH1A1 1683/4885
US-20020115067-A1 Asymmetric benzoxanthene dye labelling reagents POLL, DUT, IPO5 SMAD3 4294/4885HPGD 3460/4885ALDH1A1 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.